Rosendahl Huber A, van Leeuwen AJCN, Peci F, de Kanter JK, Bertrums EJM, van Boxtel R. Whole-genome sequencing and mutational analysis of human cord-blood derived stem and progenitor cells.
STAR Protoc 2022;
3:101361. [PMID:
35573477 PMCID:
PMC9092504 DOI:
10.1016/j.xpro.2022.101361]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
Mutational signatures have been identified in cancer genomes, providing information about the causes of cancer and treatment vulnerabilities. This protocol describes an assay to determine the genotoxic mechanisms underlying these signatures using cord-blood derived hematopoietic stem and progenitor cells (CB-HSPCs). CB-HSPCs have a low mutation background, enabling sensitive detection of mutations. First, CB-HSPCs are exposed in vitro, sorted, and clonally expanded. This expansion enables whole-genome sequencing to detect the mutation load and respective patterns induced during genotoxic exposure.
For complete details on the use and execution of this protocol, please refer to de Kanter et al. (2021).
Experimentally defining mutational signatures in cord blood-derived stem cells
Whole genome sequencing of exposed stem cell allows detection of all mutation types
Low intrinsic mutation burden of cord blood-derived stem cells increases sensitivity
Collapse